KBC Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$56.8M Sell
127,208
-13,912
-10% -$6.49M 0.14% 139
2025
Q4
$64M Buy
141,120
+7,518
+6% +$3.24M 0.15% 130
2025
Q3
$52.3M Buy
133,602
+937
+0.7% +$392K 0.13% 146
2025
Q2
$59.1M Buy
132,665
+13,360
+11% +$6.16M 0.16% 127
2025
Q1
$57.8M Sell
119,305
-124
-0.1% -$57.8K 0.18% 132
2024
Q4
$48.1M Buy
119,429
+22,702
+23% +$10.5M 0.13% 151
2024
Q3
$45M Buy
96,727
+9,685
+11% +$4.65M 0.14% 153
2024
Q2
$40.8M Buy
87,042
+4,870
+6% +$2.11M 0.12% 151
2024
Q1
$34.3M Sell
82,172
-19,102
-19% -$8.08M 0.11% 185
2023
Q4
$41.2M Buy
101,274
+874
+0.9% +$323K 0.15% 157
2023
Q3
$34.9M Sell
100,400
-116,478
-54% -$40.7M 0.14% 156
2023
Q2
$76.3M Buy
216,878
+24,800
+13% +$8.36M 0.31% 71
2023
Q1
$60.5M Sell
192,078
-62,249
-24% -$18.7M 0.26% 84
2022
Q4
$73.4M Buy
254,327
+352
+0.1% +$107K 0.36% 61
2022
Q3
$73.5M Sell
253,975
-36,001
-12% -$10.4M 0.38% 58
2022
Q2
$81.7M Buy
289,976
+11,537
+4% +$3.09M 0.41% 60
2022
Q1
$72.7M Sell
278,439
-306,815
-52% -$72.8M 0.29% 89
2021
Q4
$129M Buy
585,254
+305,091
+109% +$59.3M 0.42% 57
2021
Q3
$50.8M Sell
280,163
-312,129
-53% -$60.9M 0.19% 130
2021
Q2
$119M Buy
592,292
+86,264
+17% +$18M 0.22% 114
2021
Q1
$109M Buy
506,028
+16,836
+3% +$3.7M 0.22% 116
2020
Q4
$636M Buy
489,192
+192,756
+65% +$44.2M 0.27% 90
2020
Q3
$80.7M Buy
296,436
+51,938
+21% +$14.3M 0.24% 95
2020
Q2
$71M Buy
244,498
+145,258
+146% +$39.4M 0.24% 102
2020
Q1
$23.6M Sell
99,240
-15,529
-14% -$3.56M 0.2% 119
2019
Q4
$25.1M Sell
114,769
-481
-0.4% -$97.3K 0.16% 158
2019
Q3
$19.5M Buy
115,250
+20,332
+21% +$3.6M 0.14% 174
2019
Q2
$17.4M Buy
94,918
+19,020
+25% +$3.33M 0.13% 194
2019
Q1
$14M Buy
75,898
+12,963
+21% +$2.39M 0.11% 223
2018
Q4
$10.4M Buy
62,935
+28,069
+81% +$4.86M 0.12% 221
2018
Q3
$6.72M Buy
34,866
+10,419
+43% +$1.86M 0.05% 368
2018
Q2
$4.16M Buy
24,447
+4,834
+25% +$749K 0.04% 444
2018
Q1
$3.2M Sell
19,613
-3,115
-14% -$509K 0.03% 473
2017
Q4
$3.41M Sell
22,728
-6,429
-22% -$952K 0.03% 463
2017
Q3
$4.43M Buy
29,157
+2,769
+10% +$417K 0.04% 420
2017
Q2
$3.4M Sell
26,388
-978
-4% -$118K 0.03% 465
2017
Q1
$2.99M Sell
27,366
-31,073
-53% -$2.74M 0.03% 543
2016
Q4
$4.3M Sell
58,439
-17,535
-23% -$1.43M 0.04% 431
2016
Q3
$6.63M Sell
75,974
-25,288
-25% -$2.39M 0.08% 286
2016
Q2
$8.71M Buy
101,262
+6,055
+6% +$523K 0.12% 197
2016
Q1
$7.57M Buy
95,207
+52,584
+123% +$4.76M 0.13% 209
2015
Q4
$5.36M Buy
42,623
+14,759
+53% +$1.78M 0.1% 246
2015
Q3
$2.9M Sell
27,864
-21,758
-44% -$2.8M 0.06% 357
2015
Q2
$6.13M Sell
49,622
-9,435
-16% -$1.19M 0.08% 291
2015
Q1
$6.97M Buy
59,057
+12,704
+27% +$1.52M 0.09% 257
2014
Q4
$5.51M Buy
46,353
+37,171
+405% +$4.19M 0.07% 333
2014
Q3
$1.03M Sell
9,182
-9,891
-52% -$942K 0.04% 509
2014
Q2
$1.81M Sell
19,073
-1,377
-7% -$96.6K 0.02% 619
2014
Q1
$1.45M Sell
20,450
-17,046
-45% -$1.35M 0.02% 567
2013
Q4
$2.79M Buy
37,496
+16,520
+79% +$1.15M 0.04% 429
2013
Q3
$1.59M Sell
20,976
-14,829
-41% -$1.18M 0.03% 567
2013
Q2
$2.87M Buy
+35,805
New +$2.64M 0.05% 410

Other funds holding VRTX

KBC Group's VRTX Position: Q1 2026 in Review

KBC Group reduced its Vertex Pharmaceuticals (VRTX) stake by 9.9% in Q1 2026, selling an estimated $6.49M and leaving 127,208 shares worth $56.8M. The position accounts for 0.14% of the portfolio, ranked #139.

KBC Group first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $636M in Q4 2020. 1,688 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • KBC Group held 127,208 shares of Vertex Pharmaceuticals worth $56.8M as of Q1 2026.
  • KBC Group sold 13,912 Vertex Pharmaceuticals shares in Q1 2026, an estimated $6.49M.
  • Vertex Pharmaceuticals made up 0.14% of KBC Group's portfolio in Q1 2026, its #139 holding.
  • KBC Group first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • KBC Group's Vertex Pharmaceuticals position peaked at $636M in Q4 2020.
  • 1,688 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.